Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 147 of the 147 references it cites were found in a registry or an index; 114 of the 199 sources its claims cite were checked for support.

Histone modifications and depression: epigenetic mechanisms, therapeutic targets, and translational outlook

Open access
Lv, Liang-Zhen, Wang, Zhao-Di, Ren, Jia-jie, Li, Lu-Hao, Liu, Xian-bao, Li, Jia-li, Zhu, Hui, Jiang, Bei, Han, Ya-peng, Zhou, Xue-ming, Ren, Li, Chang, Zhuo · 2026 · Frontiers in Genetics

Abstract

Major depressive disorder (MDD) is a highly prevalent and heterogeneous psychiatric disorder shaped by the interplay of genetic, environmental, and epigenetic factors. Histone modifications, particularly acetylation and methylation, have emerged as critical regulators of chromatin dynamics and gene expression in stress adaptation, neuroplasticity, and emotional regulation. This review synthesizes current evidence linking dysregulated histone deacetylases (HDACs) and histone methyltransferases (HMTs) to impaired neuroplasticity, neuroinflammation, mitochondrial dysfunction, and hypothalamic–pituitary–adrenal (HPA) axis hyperactivity in depression. We further evaluate the therapeutic potential of HDAC and HMT inhibitors, highlight their effects beyond transcriptional control, and discuss peripheral epigenetic biomarkers as candidate tools for patient stratification and treatment prediction. Emerging technologies, including single-cell and spatial epigenomics as well as CRISPR-based epigenetic editing, are outlined as future avenues toward precision medicine. While isoform specificity, off-target effects, and translational heterogeneity remain major challenges, targeting histone modifications represents a promising strategy for next-generation antidepressant development.

Overview

CoChat Summary

TL;DR

This narrative review synthesizes evidence that dysregulated histone acetylation and methylation—chiefly via HDACs and HMTs—contribute to depression pathophysiology through impaired neuroplasticity, neuroinflammation, mitochondrial dysfunction, and HPA-axis hyperactivity, and evaluates HDAC/HMT inhibitors as candidate antidepressants. It concludes that clinical translation remains early-stage, constrained by isoform specificity, off-target effects, and translational heterogeneity.

Key findings

  • MDD affects over 280 million individuals globally, with global prevalence rising nearly 50% over the past three decades; histone hypoacetylation at H3K9ac and H4K12ac in hippocampus and prefrontal cortex is associated with reduced BDNF, SLC6A4, CREB, and monoamine-synthesis enzymes (TH, TPH) in chronic stress models.
  • The mammalian HDAC family comprises 18 isoforms in four classes (I–IV); Class I and II isoforms appear most relevant to depression, with HDAC2/5 activity increased by chronic stress and HDAC5-mediated H4K12 deacetylation linked to stress vulnerability.
  • Repressive methylation marks H3K9me3 (SETDB1) and H3K27me3 (EZH2) silence mood-relevant genes: SETDB1 loss derepresses Htr3a in cortical GABAergic interneurons producing anxiety/depression-like behavior in mice (partially reversed by 5-HT3 antagonists), while EZH2 inhibitors GSK126 and EPZ-6438 (tazemetostat) alleviate depressive-like behavior in preclinical models.
  • HDAC inhibitors (SAHA, entinostat) show antidepressant, anti-inflammatory, and metabolic effects in animal models, but direct human evidence in depression is limited and large-scale randomized controlled trials are lacking; SAHA and entinostat have reached phase I/II oncology trials only.

Methods

  • Narrative review integrating preclinical (rodent chronic unpredictable stress, chronic social defeat stress, prenatal stress), cellular, and clinical literature on histone modifications in MDD.
  • Covers nucleosome biology, writer/eraser/reader enzymology, region- and sex-specific chromatin alterations (PFC, NAc, hippocampus/DG), HDAC/HMT pharmacology, peripheral biomarkers, and emerging technologies (single-cell/spatial epigenomics, CRISPR-dCas9 editing).
  • No primary data, systematic search protocol, or meta-analysis is reported.

Limitations

  • Stated: HDAC inhibitors display limited isoform selectivity and off-target activity; broad-spectrum inhibition raises systemic and neurocognitive safety concerns; epigenetic drugs act on interconnected networks with compensatory responses; temporal, regional, and cellular heterogeneity complicate prediction; animal models incompletely capture clinical heterogeneity, chronicity, and symptom profiles, with species-specific epigenetic differences; peripheral biomarkers lack multicenter longitudinal validation and their reflection of central pathology is uncertain; clinical evidence in depression remains early-phase.
  • Evident from the text: as a narrative review without a stated search strategy or quality appraisal, the synthesis is selective and does not quantify effect sizes or assess risk of bias across cited studies; several mechanistic claims rest on non-depression models (spinal cord injury, UVB photoaging, cellular senescence, Alzheimer's disease).

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3389/fgene.2025.1722453

Cites

147 of 147 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

FIGURE 1 This figure summarizes a multilayered framework linking histone modifications to the pathophysiology and treatment of depression. The central core highlights histone modifications as a key epigenetic hub. The inner ring depicts major regulatory mechanisms, including histone acetylation (HDACs), histone methylation (HMTs/KDMs), chromatin accessibility, and metabolism-linked modifications such as histone lactylation. The middle ring illustrates downstream biological processes influenced by these mechanisms, including neuroplasticity, neuroinflammation, mitochondrial metabolism, and stress response via the HPA axis. The outer ring outlines translational perspectives, encompassing epigenetic modulators, precision medicine and biomarkers, and emerging technologies. Together, this framework integrates molecular regulation, functional consequences, and translational outlooks in depression.
FIGURE 1 This figure summarizes a multilayered framework linking histone modifications to the pathophysiology and treatment of depression. The central core highlights histone modifications as a key epigenetic hub. The inner ring depicts major regulatory mechanisms, including histone acetylation (HDACs), histone methylation (HMTs/KDMs), chromatin accessibility, and metabolism-linked modifications such as histone lactylation. The middle ring illustrates downstream biological processes influenced by these mechanisms, including neuroplasticity, neuroinflammation, mitochondrial metabolism, and stress response via the HPA axis. The outer ring outlines translational perspectives, encompassing epigenetic modulators, precision medicine and biomarkers, and emerging technologies. Together, this framework integrates molecular regulation, functional consequences, and translational outlooks in depression.CC BY · PubMed Central
FIGURE 2 HDAC-mediated mechanisms in depression and therapeutic intervention. Chronic stress increases HDAC2/5 activity, leading to reduced histone acetylation, suppression of BDNF/CREB, impaired synaptic plasticity, and depressive phenotypes. HDAC inhibitors restore acetylation, upregulate BDNF/CREB, and improve plasticity and mood. Beyond transcriptional repression, HDACs also modulate neuroinflammation (↑IL-1β, IL-6, TNF-α), mitochondrial metabolism (↓OXPHOS, ↑ROS), and HPA axis activity (↑cortisol), providing additional pharmacological entry points for antidepressant development (Jiang et al., 2025).
FIGURE 2 HDAC-mediated mechanisms in depression and therapeutic intervention. Chronic stress increases HDAC2/5 activity, leading to reduced histone acetylation, suppression of BDNF/CREB, impaired synaptic plasticity, and depressive phenotypes. HDAC inhibitors restore acetylation, upregulate BDNF/CREB, and improve plasticity and mood. Beyond transcriptional repression, HDACs also modulate neuroinflammation (↑IL-1β, IL-6, TNF-α), mitochondrial metabolism (↓OXPHOS, ↑ROS), and HPA axis activity (↑cortisol), providing additional pharmacological entry points for antidepressant development (Jiang et al., 2025).CC BY · PubMed Central

Verification

Claims the paper makes

80 Valid · 10 Not valid · 42 Not checked · 69 Own results and interpretations

96 more claims · 36 with their cited sources checked

Create a free account to see all 201 claims and to verify the 2 references still open.

See all claims — free account
  • It may state two separate claims as one. 90
  • Probably not a substantial claim. 17

Create a free account to see these claims.

Citations

Cites

Show all 147 references

Research works printed but not linked: 1

  1. 2025, Depressive disorder (depression)

Cited by

See all 7

Metadata

Authors
Lv, L.-Z., Wang, Z.-D., Ren, J.-J., Li, L.-H., Liu, X.-B., Li, J.-L., Zhu, H., Jiang, B., Han, Y.-P., Zhou, X.-M., Ren, L., & Chang, Z.
Affiliations
  • Heilongjiang University of Chinese Medicine (CN)
  • Zhejiang Chinese Medical University (CN)
  • Guangdong Medical College (CN)
Corresponding author
Chang, Zhuo
Venue
Frontiers in Genetics
Published
2026-01-12
Volume
16
Pages
1722453-1722453
ISSN
1664-8021 (ISSN-L)
OpenAlex
W7122721022
Cited by
7
References
147
Citations by year
2026: 7
FWCI
4.66
Type
journal article
Language
en
Open access
Locations
  • Frontiers in Genetics (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • PubMed Central (publishedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Natural Science Foundation of China (82205163, 82174421)
  • Natural Science Foundation of Heilongjiang Province (PL2024H220)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
Keywords
histone modifications, major depressive disorder, histone deacetylase, histone methyltransferase, histone deacetylase inhibitors, epigenetic biomarkers, neuroplasticity, neuroinflammation, mitochondrial dysfunction, HPA axis hyperactivity, stress adaptation, emotion regulation, antidepressant drug development, precision medicine, spatial epigenomics, chromatin dynamics

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Histone modifications and depression: epigenetic mechanisms, therapeutic targets, and translational outlook. https://app.cochat.ai/papers/10.3389/fgene.2025.1722453
The paper
Lv, L.-Z., Wang, Z.-D., Ren, J.-J., Li, L.-H., Liu, X.-B., Li, J.-L., Zhu, H., Jiang, B., Han, Y.-P., Zhou, X.-M., Ren, L., & Chang, Z. (2026). Histone modifications and depression: epigenetic mechanisms, therapeutic targets, and translational outlook. Frontiers in Genetics. https://doi.org/10.3389/fgene.2025.1722453

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.